Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695303 | 0.94 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2AATMSIGMAR1 | |
| SCHEMBL4697388 | 0.86 | CACNA1B (0.36) | CHRM2HTR1AADRA2ADRD1SLC6A4 | |
| SCHEMBL4694103 | 0.85 | L3MBTL1 (0.39) | L3MBTL1MEN1KMT2AATMSIGMAR1 | |
| SCHEMBL4692174 | 0.83 | CACNA1H (0.32) | DRD3 | |
| SCHEMBL4693266 | 0.79 | ADRB2 (0.34) | CHRM2HTR1AADRA2ADRD1SLC6A4 | |
| SCHEMBL4695753 | 0.78 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2ASIGMAR1RECQL | |
| SCHEMBL3884659 | 0.77 | KDM4E (0.36) | MEN1KMT2AATMSIGMAR1KDM4E | |
| SCHEMBL4693276 | 0.77 | LMNA (0.35) | L3MBTL1MEN1KMT2AATMSIGMAR1 | |
| SCHEMBL4695231 | 0.77 | POLB (0.54) | L3MBTL1MEN1KMT2AKDM4ERECQL | |
| SCHEMBL4692914 | 0.77 | ADRB2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509528-B1 | 1,3-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2008-09-24 | — | — | EP | claimed |
| EP-1684749-B1 | USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-05 | — | — | EP | claimed |
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-06-07 | — | — | US | claimed |
| US-7166583-B2 | 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-01-23 | — | — | US | claimed |
| US-20050227963-A1 | 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2005-10-13 | — | — | US | claimed |
| EP-1684749-B1 | USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-05 | — | — | EP | disclosed |
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, BCHE, DDT | L3MBTL1 1797/4885MEN1 318/4885KMT2A 2852/4885 |
| US-20050227963-A1 | 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | IL1A, TNF, IL1B | L3MBTL1 1572/4885MEN1 828/4885KMT2A 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.